These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35978873)

  • 41. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
    Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
    J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China.
    Li J; Sun A; Zhong G; He Y; Xiong H; Yuan X
    J Int Med Res; 2021 Nov; 49(11):3000605211061040. PubMed ID: 34851763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
    Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
    Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.
    Igarashi T; Shimizu K; Usui K; Yokobori T; Ohtaki Y; Nakazawa S; Obayashi K; Yajima T; Nobusawa S; Ohkawa T; Katoh R; Motegi Y; Ogawa H; Harimoto N; Ichihara T; Mitani Y; Yokoo H; Mogi A; Shirabe K
    Int J Clin Oncol; 2020 Apr; 25(4):641-650. PubMed ID: 31773354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients.
    Lima J; Teixeira Y; Pimenta C; Felipe AV; Silva TD; Junior EEDL; Saad SS; Deak E; Murray H; Manoukian Forones N
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2929-2934. PubMed ID: 31653137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening.
    Chen J; Lin J; Zhang L; Chen M; Yu X; Wu Y; Wang T; Xu R; Tian T; Sun A; Zhang T; Lu Y; Ba Z; Cheng X; Chen M
    Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
    Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
    Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.